Alnylam Pharmaceuticals IncChange company Symbol lookupSelect an option...ALNY Alnylam Pharmaceuticals IncRHHBY Roche Holding AGEGP Eastgroup Properties IncPMT PennyMac Mortgage Investment TrustGS Goldman Sachs Group IncHLBZ Helbiz IncSRNE Sorrento Therapeutics IncOKTA Okta IncAAPL Apple IncCBTTF Cathedra Bitcoin IncGo
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| April 28, 2022 | Q1 2022 Earnings Release | -$2.00 | -$2.14 to -$1.16 | -$1.71 |
| February 10, 2022 | Q4 2021 Earnings Release | -$2.16 | -$1.97 to -$1.12 | -$2.09 |
| October 28, 2021 | Q3 2021 Earnings Release | -$1.72 | -$2.01 to -$1.25 | -$2.18 |
| August 3, 2021 | Q2 2021 Earnings Release | -$1.61 | -$1.98 to -$1.14 | -$1.56 |
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
, , , Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.